LINC00484: A Potential Drug Target and Biomarker (G100129347)

Target Name: LINC00484

NCBI ID: G100129347

LINC00484

Other Name(s): long intergenic non-protein coding RNA 484 | C9orf73 | LINC00484 variant X4 | Long intergenic non-protein coding RNA 484, transcript variant X4

LINC00484: A Potential Drug Target and Biomarker

LINC00484 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-derived suppressor (MDS) gene family, which plays a critical role in the development and maintenance of immune cells. MDS cells are often found in the bone marrow and are responsible for producing antibodies that help to protect the body against infections and diseases.

The MDS gene family is a large gene family that includes several highly conserved genes that are involved in the regulation of hematopoietic stem cell (HSC) proliferation and differentiation. The MDS genes are characterized by the presence of a specific C-terminal region, which is responsible for the regulation of stem cell proliferation and the development of blood cells.

LINC00484 is a member of the MDS gene family and is located at position -139.4 kcal on the UniProt protein data base. It is a small non-coding RNA molecule that contains only four amino acid residues. LINC00484 is expressed in a variety of tissues and cells, including blood cells, immune cells, and tissues.

Potential Drug Target

The MDS gene family has been implicated in the development and maintenance of a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. LINC00484 is a potential drug target because it is involved in the regulation of stem cell proliferation and differentiation, which are important processes that are involved in the development and maintenance of many diseases.

LINC00484 is a good candidate for a drug because it is involved in the regulation of a critical pathway that is involved in the development and maintenance of many diseases. For example, LINC00484 is involved in the regulation of the p53 pathway, which is a critical pathway that is involved in the regulation of DNA damage repair, cell cycle progression, and apoptosis.

Biomarker

LINC00484 may also be a useful biomarker for the diagnosis and treatment of various diseases. For example, LINC00484 may be used as a biomarker for the diagnosis of cancer, as it is often overexpressed in cancer cells. It may also be used as a biomarker for the diagnosis of neurodegenerative diseases, as it is often overexpressed in these diseases.

LINC00484 is also a good candidate for a diagnostic biomarker for autoimmune disorders, as it is often overexpressed in these disorders. For example, LINC00484 is often overexpressed in conditions such as rheumatoid arthritis, lupus, and multiple sclerosis.

Conclusion

In conclusion, LINC00484 is a potential drug target and biomarker that has the potential to improve the treatment outcomes for a variety of diseases. Further research is needed to fully understand the role of LINC00484 in the regulation of stem cell proliferation and differentiation, as well as its potential as a biomarker for the diagnosis and treatment of various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 484

The "LINC00484 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00484 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets